Fluoroquinolones

Oral absorption is diminished by coadministration of polyvalent cations (aluminum, magnesium, calcium, zinc, and iron preparations). After oral and parenteral administration, fluoroquinolones are widely distributed in most extracellular and intracellular fluids and are concentrated in the prostate, lungs, and bile.

Fluoroquinolones are active against the following:

• Haemophilus influenzae

• Moraxella catarrhalis

• Mycoplasma species

• Chlamydia species

• Chlamydophila species

• Legionella species

• Enterobacterales (formerly Enterobacteriaceae)

• Pseudomonas aeruginosa

• Mycobacterium tuberculosis

• Some atypical mycobacteria

• Some methicillin-sensitive staphylococci

Nosocomial methicillin-resistant staphylococci (MRSA) are usually resistant. Older fluoroquinolones have poor activity against streptococci and anaerobes. Newer fluoroquinolones have reliable activity against streptococci (including Streptococcus pneumoniae with reduced penicillin sensitivity) and some anaerobes

• Gram-negative bacteria including Pseudomonas aeruginosa

• Gram-positive bacteria including MRSA, as well as atypical respiratory tract pathogens

• Anaerobes

As fluoroquinolone use has increased, resistance, particularly to older fluoroquinolones, is developing among Enterobacterales, P. aeruginosa, S. pneumoniae, and Neisseria species. Nonetheless, fluoroquinolones have many clinical uses (see table Some Clinical Uses of Fluoroquinolones).

N. gonorrhoeae that are susceptible to the antibiotic.

Contraindications include

• Previous allergic reaction to the medications

• Certain disorders that predispose to arrhythmias (eg, QT-interval prolongation, uncorrected hypokalemia or hypomagnesemia, significant bradycardia)

Fluoroquinolones have traditionally been contraindicated in children because they may cause cartilage lesions if growth plates are open. However, many experts, including the American Academy of Pediatrics (AAP), challenge this view because evidence is weak, and they recommend prescribing fluoroquinolones as a second-line antibiotic and restricting use to a few specific situations when there are no reasonable alternatives, including P. aeruginosa infections in patients with cystic fibrosis, prophylaxis and treatment of bacterial infections in patients who are immunocompromised, life-threatening multiresistant bacterial infections in neonates and infants, and Salmonella or Shigella gastrointestinal tract infections (1).

Animal reproduction studies with fluoroquinolones show some risk. Data related to pregnancy in humans are limited. Fluoroquinolones should be used in pregnancy only if clinical benefit exceeds risk and a safer alternative is not available.

Fluoroquinolones enter breast milk. Use during breastfeeding is not recommended.

Fluoroquinolones have boxed warnings because they have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together including

• Tendinopathy, including rupture of the Achilles tendon, may occur even after short-term use of fluoroquinolones.

• Peripheral neuropathy may occur soon after taking the fluoroquinolone and may be permanent. If symptoms (eg, pain, burning, tingling, numbness, weakness, change in sensation) occur, use of the fluoroquinolone should be stopped to prevent irreversible damage.

• Central nervous system (CNS) adverse effects include seizures, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis. Other CNS adverse effects include nervousness, anxiety, agitation, insomnia, nightmares, dizziness, mood alteration, paranoia, confusion, tremors, hallucinations, and depression. Seizures are rare, but fluoroquinolones should not be used in patients with CNS disorders.

• Muscle weakness may be exacerbated in patients with myasthenia gravis, so fluoroquinolones should be avoided in these patients.

Other adverse effects include

• Upper gastrointestinal adverse effects occur in about 5% of patients because of direct gastrointestinal irritation.

• Hypoglycemia can occur, especially when a fluoroquinolone is combined with antihyperglycemic medications.

• QT-interval prolongation can occur, potentially leading to ventricular arrhythmias and sudden cardiac death.

• Aortic aneurysm and dissection can occur, with a potentially increased risk in patients who have risk factors for aortic aneurysm (eg, Marfan syndrome) or who have a known aortic aneurysm.

• Clostridioides (formerly Clostridium) difficile–associated diarrhea (pseudomembranous colitis) has been strongly associated with fluoroquinolone use, especially that due to the hypervirulent C. difficile ribotype 027.

• Hypersensitivity reactions (including anaphylactic reactions) may occur after the first dose or subsequent doses. Fluoroquinolone use should be stopped at the first sign of rash, jaundice, or any sign of hypersensitivity.

• Hepatotoxicity can occur. Fluoroquinolone use should be stopped immediately if hepatitis occurs.

• Photosensitivity can occur, resulting in exaggerated sunburn reactions. Patients taking fluoroquinolones should avoid excessive ultraviolet exposure.

> 1 week and is more likely to develop in women < 40 years of age. Nephrotoxicity is rare.

Ciprofloxacin raises